secwatch.observer — SEC 8-K summary
======================================

Issuer:     IMMUCELL CORP /DE/ (ICCC)
CIK:        0000811641
Form:       8-K
Filed at:   2025-01-10T23:59:59+00:00
Accession:  0001213900-25-002326
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ImmuCell reports preliminary Q4 2024 sales of $7.8M, up 52% YoY; full year $26.5M
--------------------------------------------------------------------------------

- Q4 2024 product sales $7.8M vs $5.1M in Q4 2023 (+52%); FY2024 sales $26.5M vs $17.5M (+52%).
- Annualized Q4 production output ~103% of estimated $30M/year capacity; backlog fell to $4.4M from $9.4M.
- Contract manufacturer submitted response to FDA inspection observations; company filed Non-Administrative NADA for Re-Tain® in January.
- Conference call to discuss full unaudited results on February 26, 2025 at 9:00 AM ET.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/811641/000121390025002326/0001213900-25-002326-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/811641/000121390025002326/ea0227158-8k_immucell.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-002326

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer